AMDL Launches Expanded Distribution With 3rd Round of Agreements Valued at $6.84 Million Annually for New Health & Beauty Produc
November 02 2007 - 8:49AM
PR Newswire (US)
TUSTIN, Calif., Nov. 2 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), with operations in Shenzhen, Jiangxi and Jilin, China,
through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI),
which is an international biopharma company that engages in the
development, manufacture and marketing of proprietary
pharmaceutical and diagnostic products, announced today that its
JPI's subsidiary JJB has signed the third round of regional
distribution agreements for its new anti-aging and skin care
injectable product under the brand name "Goodnak." This initial
product is the first in a new line of anti-aging & skin care
products currently under development by JJB. JJB has signed three
new Western Regional exclusive, one-year renewable Distribution and
Agency Agreements that were signed between Jade Pharma's subsidiary
JJB and Xian Maryland Cosmetics Co., Ltd. ("XMC"), Lanzhou Charm
Trade Co., Ltd. ("LCT") and Wulumuqi Ozi Cosmetics Co., Ltd.
("WOC"). These agreements cover the key cities in Shanxi, Xinjiang
and Gansu Provinces that have a combined population of
approximately 86 million people. These two separate agreements in
combination, require these new distributors to purchase a minimum
of US$6,844,206 of JJB's new HPH product during the one-year period
of the contracts and a minimum initial order of US$3,422,102. Frank
Zheng, managing director of JPI, said these third round of
additional distribution agreements puts the Company on the path to
building sales of Goodnak by as much as $24 million over the next
12 months. These agreements, coupled with the previously announced
agreements, provide JJB with a current total of approximately
$17.31 million in anticipated orders for its new Goodnak product.
Gary Dreher, CEO of AMDL said, we expect to further update the
market on our expansion plans in the coming weeks. About Goodnak:
Goodnak is a high quality injectable anti-aging & skin care
product that contains an amalgam of various therapeutic elements
including human placental histosolution ("HPH"). JPI has begun
selling Goodnak, in August, through wholesale distribution channels
that service high-end beauty salon and plastic surgery hospitals
and or medical cosmetology institutions. Goodnak product
information is available on Jade Pharma's product specific website:
http://www.jade-amdl.com/. About JPI: Jade Pharmaceutical through
its subsidiaries JJB & YYB has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiary, Jade currently manufactures large volume
injectable fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, AMDL Investor Relations,
+1-949-707-5365, VoiceMail, +1-714-505-4460 Web site:
http://www.amdl.com/ http://www.jade-amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024